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Introduction
In mammalian female cells, the faithful localization in cis of 
XIST RNA across one X chromosome is the initiating step 
in its subsequent silencing. Thus, the mechanism by which 
this unusual chromosomal RNA localizes to, spreads across, 
and stably binds its chromosome of origin is essential to its 
function. 15 yr after the discovery of XIST RNA (Brown   
et al., 1992), almost nothing is known about what regulates 
XIST RNA binding to the chromosome. Despite long-standing 
attempts by many laboratories to isolate or identify proteins 
in a specific XIST RNA “complex” using standard biochem-
ical approaches (Brown and Baldry, 1996; for review see 
Brockdorff, 2002), there still has been very little success, 
possibly because of the tight association of the RNA with 
nuclear structure. XIST RNA is so tightly bound at inter-
phase that it remains localized under a variety of fixation 
and extraction conditions, including extensive nuclear matrix 
extraction  procedures  (Clemson  et  al.,  1996).  The  latter   
observation  suggests  that  the  RNA  is  unlikely  bound  by   
hybridization to DNA, but even this is not known for certain. 
A study using mouse XIST RNA transgene constructs reported 
that multiple parts of the XIST RNA promote its localiza-
tion (Wutz et al., 2002), which suggests that each large (14 kb) 
XIST RNA transcript may bind more than one site on the 
chromosome/chromatin. In contrast to the faithful chromo-
somal localization at interphase, this tight binding is lost at 
mitosis, during which the RNA can be seen visibly released 
from the inactive chromosome and appears by RNA FISH as 
bright punctate dots distributed throughout the cytoplasm 
(Clemson et al., 1996; this study). Identification of defined 
conditions that release XIST RNA from the chromosome   
at interphase or maintain binding during mitosis would be 
significant for breaking the impasse in understanding the   
underlying mechanism of XIST RNA localization and chro-
mosome binding.
  H
ow XIST RNA strictly localizes across the inactive 
X chromosome is unknown; however, prophase 
release of human XIST RNA provides a clue. Tests 
of inhibitors that mimic mitotic chromatin modifications 
implicated an indirect role of PP1 (protein phospha-
tase  1),  potentially  via  its  interphase  repression  of   
Aurora B kinase (AURKB), which phosphorylates H3 and 
chromosomal  proteins  at  prophase.  RNA  interference 
to AURKB causes mitotic retention of XIST RNA, unlike 
other mitotic or broad kinase inhibitors. Thus, AURKB 
plays an unexpected role in regulating RNA binding to 
heterochromatin, independent of mechanics of mitosis. 
H3 phosphorylation (H3ph) was shown to precede XIST 
RNA  release,  whereas  results  exclude  H1ph  involve-
ment. Of numerous Xi chromatin (chromosomal protein) 
hallmarks, ubiquitination closely follows XIST RNA reten-
tion or release. Surprisingly, H3S10ph staining (but not 
H3S28ph) is excluded from Xi and is potentially linked 
to ubiquitination. Results suggest a model of multiple dis-
tinct anchor points for XIST RNA. This study advances 
understanding  of  RNA  chromosome  binding  and  the 
roles of AURKB and demonstrates a novel approach to 
manipulate and study XIST RNA.
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et al., 1997; Zhang et al., 2005) but also inhibit PP1 at 10–100-
fold higher concentrations (Bialojan and Takai, 1988; Knapp 
et al., 1998). In this study, we find that concentration ranges 
specific for PP2A (<5 µM CANTH and <170 nM OKA) do not 
result in substantially mislocalized XIST RNA (Fig. 1 G and 
Fig. S1 B) and that only concentrations much higher than those 
reported to be specific for PP2A inhibition (≥300 nM OKA 
and ≥10 µM CANTH) produce a significant effect on XIST 
RNA binding. However, these high levels of CANTH and OKA 
also caused premature chromosome condensation (see Fig. 5 D) 
and showed evidence of toxicity (cell loss, debris, and severely 
altered nuclear morphology; Fig. 1 F), which was not seen in 
samples using lower and more specific inhibition of PP1 by 
TAUT. This suggests that the more specific effect on XIST RNA 
localization seen by TAUT was likely caused by the specific 
inhibition of PP1, whereas the effect on XIST RNA binding 
seen at very high, nonspecific concentrations of CANTH and 
OKA may be caused by the inclusion of PP1 inhibition along 
with PP2A.
Because many phosphatases and kinases are intimately 
linked in a biochemical network, we tested whether disruption 
of XIST RNA binding was affected by a more general disrup-
tion of overall cellular phosphorylation or by lethal levels of 
chromatin modifying drugs. Using the broad range kinase in-
hibitor staurosporine (STSP), compaction of the inactive chro-
mosome appeared to be affected but not XIST RNA binding, 
even at very high concentrations (Fig. S1). Similarly, deacety-
lase inhibitors sodium butyrate (SB) and trichostatin-A (TSA), 
which dramatically increase nucleoplasmic acetylation, also 
had no effect on XIST RNA binding in both cell types at a 
broad  range  of  concentrations,  including  toxic  levels  (0.5– 
20 µM), and for 6 or 18 h (Fig. S1, D and E). Thus, broad con-
centration ranges of several inhibitors (Fig. S1 F), including 
toxic levels, had no apparent impact on XIST RNA binding in 
the cell lines tested, and only the PP1 inhibitor TAUT induced 
significant release of XIST RNA at low concentrations in   
interphase (Fig. 1 G).
Inhibitors of PP1 may indirectly affect 
XIST RNA binding via activation  
of AURKB, which impacts  
chromatin phosphorylation
We  next  considered  what  proteins  or  processes  might  be   
affected by PP1 activity, with emphasis on chromatin changes 
that also occur at mitosis. However, because phosphorylation is 
known to impact mRNA splicing factors (Misteli and Spector, 
1999; Huang and Steitz, 2005; Clemson et al., 2006), we first 
considered whether a block in splicing might play a role in 
XIST RNA mislocalization. We previously demonstrated that 
simultaneous two-color hybridization with intron and cDNA 
probes  allowed  discrimination  of  spliced  versus  unspliced   
nuclear  RNA  accumulations  (Xing  et  al.,  1995;  Clemson   
et al., 1996; Johnson et al., 2000). Using this approach, we 
found that TAUT-treated cells show efficient splicing, as judged 
by the splicing of introns 1 and 2, because treated and control 
cells  show  the  same  small  focus  of  intron  signal  within   
the larger cloud of mature XIST RNA (Fig. 2, A and B).   
One  could  imagine  that  XIST  RNA  binding  might  be 
compromised during mitosis as the result of steric constraints 
imposed as DNA condenses, or, if XIST RNA is bound through 
chromosomal proteins, biochemical changes to chromatin may 
directly alter binding affinity. Unlike the more permanent chro-
matin modifications on the Xi that follow the initial spread of 
XIST  RNA,  mitotic  modifications,  particularly  phosphoryla-
tion, are transient (Barber et al., 2004; for review see Nowak and 
Corces, 2004), as is the change in XIST RNA binding. Thus, we 
reasoned that a new approach based on investigating what con-
trols these in situ changes in XIST RNA chromosomal associa-
tion may yield inroads into what has been an intractable problem. 
In this study, we began by testing several manipulations that 
impact chromatin protein modifications, with emphasis on 
phosphorylation, to determine whether such perturbations alone 
could release XIST RNA in the absence of mitosis and chromo-
some condensation. We identify specific manipulations that in-
deed released XIST RNA at interphase and, more importantly, 
reciprocal manipulations that can cause XIST RNA retention on 
human metaphase chromosomes. These findings unexpectedly 
link Aurora B kinase (AURKB) activity, which has known 
effects on chromatin phosphorylation, as key to the regulation 
of this noncoding RNA’s interaction with heterochromatin.
Results
Inhibitors of PP1 (protein phosphatase 1) 
release XIST RNA from the inactive 
chromosome at interphase
We began by investigating whether the mitotic conditions that   
release XIST RNA from its normally restricted localization   
(Fig. 1, A–C) could be mimicked during interphase by increasing 
chromatin phosphorylation. Okadaic acid (OKA), cantharidin 
(CANTH), and tautomycin (TAUT) are potent, specific, and cell-
permeating inhibitors of Ser/Thr phosphatases whose cellular 
effects and specificities have been widely investigated (Knapp et al., 
1998; Dawson and Holmes, 1999; Honkanen and Golden, 2002). 
We began by testing inhibitor concentrations previously reported 
to be specific for phosphatase inhibition in intact cells but not high 
enough to produce premature chromosome condensation (Ajiro 
et al., 1996; Favre et al., 1997; Zhang et al., 2005). Using our 
standard fixation protocols (see Materials and methods), disasso-
ciation of XIST RNA from the parental chromosome was seen   
in interphase nuclei within 4–6 h of introducing 2–9 µM TAUT 
(Fig. 1). In both Tig-1 diploid fibroblasts and HT1080 G3 cells (XIST 
transgene cell line; see Materials and methods), XIST RNA 
released from the inactive chromosome and dispersed throughout 
the nucleoplasm as bright punctuate dots (Fig. 1, D and E), which 
is similar to what is seen at mitosis (Fig. 1 C). TAUT has been 
shown to be specific for PP1 inhibition at 10 µM in vivo, and in 
this study, we find that the lowest concentration (2 µM) that still 
affects XIST RNA binding (30% of the population) is at the 
lower end of this reported range (Fig. 1 G). Additionally, the nu-
clear morphology in these cells still appears fairly normal, with 
no condensation of chromosomes evident (Fig. 1, D and E).
However, OKA and CANTH inhibit PP2A at low con-
centrations in vivo (100 nM OKA and 1 µM CANTH; Favre 493 PHOSPHORYLATION BY AURKB AFFECTS XIST RNA BINDING • Hall et al.
Figure 1.  PP1 inhibition causes mislocalization 
of XIST RNA. (A and B) Normal female fibro-
blasts (Tig-1; A) and XIST transgenic HT1080 
cells (G3; B) show tightly localized XIST RNA. 
(C) XIST RNA binding is lost at mitosis (G3). 
(D and E) TAUT (TM) treatment of G3 (D) or 
Tig-1 (E) cells causes release of XIST RNA in 
interphase. (F) High levels of OKA (or CANTH) 
can cause XIST RNA drift in interphase cells. 
(D–F) Using image morphometrics (MetaMorph) 
the edges of the nucleus (from the blue channel) 
are imposed over the green channel to iden-
tify the limits of the nucleus for better viewing 
of the drifting XIST RNA signal. Note that the 
XIST  RNA  signals  remain  within  the  nucleus 
defined by the white lines. (G) Only TAUT treat-
ment effectively results in delocalization of the 
XIST RNA from its chromosome of origin at low   
(specific) concentrations. Bars, 10 µm.JCB • VOLUME 186 • NUMBER 4 • 2009   494
Furthermore, introns were not detected in the drifting XIST 
RNA signal in treated cells (Fig. 2 B). Although we did not   
directly test all potential permutations of splicing defects, this 
indicates that the mislocalization of XIST RNA was not caused by 
a general block of splicing factor activity.
The ability to release XIST RNA at interphase using in-
hibitors of protein phosphorylation supports the idea that the 
RNA’s localization depends on interaction with chromosomal 
proteins, which undergo modification at mitosis. During inter-
phase, PP1 is known to directly repress the activity of the   
kinase responsible for histone H3 phosphorylation (H3ph) at 
the beginning of mitosis, AURKB (Ajiro et al., 1996; Murnion 
et al., 2001; Edmondson et al., 2002; Sugiyama et al., 2002). 
Thus, we used an antibody raised against phosphorylated H3S10, 
and found that in TAUT-treated interphase cells, it was sharply 
increased relative to CANTH-treated and untreated controls. 
In untreated or CANTH-treated cells, H3ph is only abundant 
in mitotic cells (Fig. 2, C and D; Hendzel et al., 1997), whereas 
many  interphase  cells  (47%)  showed  high  H3ph  in  2  µM 
TAUT–treated samples (Fig. 2 E). This correlated well with the 
frequency of cells showing mislocalized XIST RNA in paral-
lel samples (Fig. 1 G), suggesting that AURKB kinase may be 
activated in cells in which XIST RNA binding was affected. 
We  tested  this  directly  by  doing  simultaneous  staining  of 
H3S10ph and XIST RNA in single cells. Even in samples in 
which the less specific 1 µM OKA was used to inhibit PP1, the 
presence of H3S10ph in interphase cells correlated to mis-
localization of XIST RNA (Fig. 2, K and L), suggesting that 
the presence of drifting XIST RNA was linked to the activation 
of AURKB.
At the same time, we found that H1ph, which is also nor-
mally elevated at mitosis (Fig. 2, F–H), was not increased in 
TAUT-treated H3ph-positive interphase cells (Fig. 2, I and J). 
This indicates that TAUT was not affecting histone phosphory-
lation more broadly because H1ph is controlled by another 
kinase at mitosis (CDC2/cyclin B). This also demonstrates that 
the high levels of H1ph seen at mitosis are not necessary for 
XIST RNA release.
These findings suggest that once PP1 is inhibited during 
interphase by TAUT, the known repression on AURKB is   
released (similar to that seen upon normal entry into mitosis), 
and H3ph is induced prematurely. Thus, inappropriate activa-
tion of AURKB may play a role in the destabilization of XIST 
RNA binding to chromatin in TAUT-treated interphase cells 
and during normal mitosis as well. To determine whether the 
effects of PP1 are via its effects on AURKB, we next examined 
inhibition of AURKB.
Inhibitors of AURKB block release of 
XIST RNA on metaphase chromosomes 
and counter interphase release induced by 
phosphatase inhibitor
If the interphase release of XIST RNA after PP1 inhibition is 
indirectly caused by the derepression of AURKB, the inverse 
should be true: the inhibition of AURKB at mitosis should 
maintain interphase-like binding conditions and retain XIST 
RNA on human metaphase chromosomes. Hesperadin (HESP) 
and ZM447439 (ZM) are small molecules identified as inhibi-
tors of AURKB kinase for chemotherapy and inhibit AURKB 
in vivo at nanomolar concentrations (Hauf et al., 2003; Yang   
et al., 2005; Agnese et al., 2007; Lipp et al., 2007). Using 
concentrations of HESP and ZM shown to inhibit AURKB in 
intact cells, we find that XIST RNA was strikingly retained 
across the human metaphase chromosome, in a manner not 
seen in untreated control cells, or control cells treated with the 
broad kinase inhibitor STSP. In two different human cell types 
(Tig-1 and G3), the vast majority of cells in metaphase control 
preps retained essentially no XIST RNA bound to the chromo-
some (Fig. 3, A and B). This was true even for mitotic cells 
that were only fixed in paraformaldehyde and cytospun with 
no additional extraction step (see Materials and methods).   
In contrast, under identical conditions, many HESP- and ZM-
treated cells had chromosomes that were completely or almost 
completely painted by XIST RNA well into metaphase, as was 
apparent on the metaphase rosette (Fig. 3 C). The retention of 
XIST RNA was apparent at metaphase, which is well past the 
point in early prophase when the binding of the RNA is nor-
mally compromised. No metaphase rosettes in control cells 
showed  this  extensive  XIST  RNA  chromosome  painting,   
although a few early metaphase cells in the untreated G3 line 
retained residual amounts, possibly because of the highly robust 
XIST RNA signal in this line. Because AURKB inhibition pre-
vents normal anaphase figures and chromosome segregation 
(such that cells release from mitosis as polyploid), only meta-
phase cells were scored in both control and treated samples. 
Results were consistent between both cell lines and over three 
different  experiments  and  were  apparent  even  on  cells  ex-
tracted with detergents and cytospun onto slides, further indi-
cating that the RNA remained tightly bound in treated cells, 
which is similar to what is seen at interphase.
Importantly,  this  mitotic  retention  of  XIST  RNA  by 
AURKB inhibitors was not caused by general effects of mitotic 
perturbation because we tested whether the same effect would 
be seen with nocodazole (NOC), which arrests cells in prometa-
phase. Thus, even though NOC perturbs mitosis even earlier 
than AURKB inhibition, it had no effect on the normal release 
of XIST RNA at prophase; results were indistinguishable from 
controls in which only very rare cells (1 in 50) showed substan-
tial XIST RNA still on the metaphase chromosome. XIST RNA 
retention by AURKB inhibitors was also not caused by inhibi-
tion of kinases in general, as STSP, which is known to inhibit 
numerous kinases in vivo (except Aurora kinases), did not cause 
mitotic retention of the RNA. AURKB not only orchestrates 
mitotic chromosome movements, it also induces major changes 
to chromatin across the chromosome arms (see Discussion). 
In HESP- and ZM-treated cells, H3ph (Fig. S4, C and D) was 
absent  from  mitotic  chromosomes,  further  indicating  that 
AURKB’s normal prophase role of chromatin phosphorylation 
across the chromosome arms was inhibited. Like XIST RNA, 
HP1 was also retained under these conditions compared with 
nontreated mitotics (Fig. S4, A and B), confirming that HP1 re-
lease is linked to H3S10ph and AURKB activity (Hauf et al., 
2003; Fischle et al., 2005; Hirota et al., 2005; Yang et al., 2005; 
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Figure  2.  Phosphatase  inhibition  affects 
H3ph not H1ph or XIST RNA splicing. (A and B) 
Untreated  and  TAUT  (TM)-treated  Tig-1  cells 
demonstrate splicing of two XIST RNA introns 
within  the  mature  XIST  RNA  accumulation. 
The  green  intron  signal  is  separated  as  an 
inset. Arrows in the main image identify two 
regions of XIST RNA signal (red); the larger 
top one remains localized to the Xi, and the 
small  bottom  one  is  drifting.  The  arrows  in 
the inset identify only the top XIST signal still 
contains intron 1 (green). The bottom arrows 
point to an example of spliced XIST RNA (lack-
ing green intron), which is mislocalized in the   
nucleoplasm. Using image morphometrics (Meta-
Morph) the edges of the nucleus (from the blue 
channel) are imposed over the green channel 
to identify the limits of the nucleus for better 
viewing of the drifting XIST RNA signal. Note 
that the XIST RNA signals remain within the 
nucleus defined by the blue lines. (C and D) In 
untreated and CANTH (CT)-treated Tig-1 cells, 
only mitotic cells stained positive for H3ph, as 
shown by the black and white inset of DAPI 
DNA stain. (E) H3ph is commonly seen in   
interphase cells upon TAUT treatment, as shown 
by the black and white insets of DAPI DNA 
stain. (F–H) Control cells (and CANTH-treated 
cells) show both H1ph and H3ph in prophase 
(F) and metaphase (G), but H1ph is lost be-
fore H3S10ph, as in anaphase/telophase (H). 
(I and J) In TAUT-treated cells, H1ph does not   
increase (J) in cells that show marked increase 
in H3S10ph (I). DAPI DNA (inset) confirms   
interphase  cells.  (K)  Increased  H3ph  in   
interphase cells is correlated with drifting XIST 
RNA in 1 µM OKA–treated G3 cells. (L) In 100 
OKA-treated cells, XIST RNA tightly localized 
to one large focal accumulation (XIST focal) 
only in cells with low H3ph (). XIST RNA was 
partially  mislocalized  (XIST  residual)  in  cells   
with high H3ph (+) and completely mislocalized 
(XIST drift) in cells with the highest H3ph (+++). 
Bars, 10 µm.JCB • VOLUME 186 • NUMBER 4 • 2009   496
Specific inhibition of AURKB by RNAi 
shows that it is required for the normal 
prophase release of human XIST RNA
Although the aforementioned results implicate the involve-
ment of AURKB kinase, pharmacological inhibitors are not 
entirely specific; for example, in some circumstances, HESP 
and ZM can also impact other Aurora kinases (Agnese et al., 
2007). Therefore, it was important to perform RNAi specifi-
cally targeted against AURKB, which we did in both Tig-1 
and  G3  cells  using  an  AURKB  SMARTpool  siRNA.  By   
optimizing  transfection  protocols,  we  achieved  50–70% 
transfection efficiencies in Tig-1 and G3 cells. Use of a robust 
immunofluorescence (IF) assay together with FISH provided 
the advantage that the impact of RNAi on AURKB could be 
assessed in individual cells simultaneously with XIST RNA. 
As  documented  in  Fig.  5,  RNAi  eliminated  any  detectable 
AURKB in over half of metaphase cells by 24 h, with another 
All of these results are consistent with the involvement of 
AURKB in XIST RNA binding and suggest that the release of 
XIST RNA at interphase by phosphatase inhibitors may occur by 
blocking the PP1 repression of AURKB. To test this, we attempted 
to rescue the interphase release of XIST RNA by simultaneously 
inhibiting PP1 and AURKB. Despite the potential for more non-
specific or toxic effects by dual pharmacological inhibitors, we were 
surprised to see that treatment with the AURKB inhibitor during 
interphase (for 2 h before PP1 inhibition) can suppress the release 
of XIST RNA, even using the more nonspecific inhibitor OKA 
(Fig. 4). This further supports that (a) the XIST RNA interphase re-
lease is a relatively specific effect of particular phosphatase inhibi-
tors, (b) the interphase release likely involves PP1 inhibition and 
the consequent activation of AURKB, and (c) increasing the poten-
tial toxic or nonspecific effects by using two drugs simultaneously 
does not further degrade XIST RNA binding but still allows inhibi-
tion of AURKB to largely rescue it.
Figure  3.  XIST RNA is retained on human 
metaphase  chromosomes  when  AURKB  is 
inhibited. (A) HESP- or AURKB RNAi–treated 
G3  cells  show  robust  XIST  RNA  retention 
(++++) on metaphase cells. (B) Control G3 
metaphase  cells  show  drifting  XIST  RNA. 
(C)  HESP  induces  marked  retention  of  XIST 
RNA on the inactive metaphase chromosome 
(arrow). D) AURKB RNAi resulted in similar 
retention of XIST RNA on the metaphase inac-
tive chromosome (arrow). Bar, 10 µm.497 PHOSPHORYLATION BY AURKB AFFECTS XIST RNA BINDING • Hall et al.
amount and frequency of retention and was reproducible in 
over six RNAi experiments (using two different cell lines). 
In addition to many metaphase chromosomes retaining XIST 
RNA, a few AURKB-inhibited cells were noted to have pro-
gressed into anaphase, with XIST RNA still associated, as illus-
trated in Fig. S5. These rare cells had substantial but incomplete 
fraction showing significantly reduced staining. All metaphase 
cells in control slides exhibit bright AURKB staining (Fig. 5, 
A and C). Importantly, the AURKB RNAi–treated cell population 
showed significant retention of XIST RNA on metaphase 
chromosomes relative to control cells (untreated and nonspecific 
RNAi controls; Fig. 3, A and D). This was evident by the 
Figure 4.  Inhibition of AURKB activity impedes 
XIST RNA release during PP1 inhibition. (A–C) 
OKA inhibition of PP1 in G3 cells causes XIST 
RNA  release  in  interphase  cells  (A  and  C), 
whereas  the  double  inhibition  of  PP1  (with 
OKA) and AURKB (with HESP) allowed the re-
tention of XIST RNA in many cells (B and C). 
The green (XIST RNA) channel is separated be-
low each image. (D and E) 1 µM OKA causes 
premature chromosome condensation in many 
cells (see DNA channel), but the retention of 
XIST RNA in OKA + HESP–treated cells occurs 
despite the premature chromosome condensa-
tion. Bars, 10 µm.JCB • VOLUME 186 • NUMBER 4 • 2009   498
Figure 5.  RNAi effectively eliminated AURKB in two different cells lines. 
(A) AURKB is abundant and localized to centromeres at metaphase in 
normal  female  fibroblasts  (Tig-1).  (B)  AURKB  is  eliminated  after  RNAi 
treatment. DAPI DNA channels are separated below. (graph) AURKB was 
essentially eliminated () in most metaphase Tig-1 or G3 cells, whereas 
some retained a low level (+) or were unaffected (+++). Error bars indicate 
the SD between the two experiments performed. (C–E) As scored in the 
graph, examples of cells showing unaffected (+++; green), reduced low 
level (+), or eliminated () AURKB. Exposures were equal for all three 
images. Bars, 10 µm.
reduction of AURKB, which was sufficient to promote XIST 
RNA retention but not to fully block anaphase progression. 
This likely relates to the dynamics and relative amounts of 
AURKB required for different functions, as considered in the 
Discussion, and provides further evidence that AURKB ef-
fects on XIST RNA binding can be separated from the me-
chanics of mitosis.
These findings clearly establish that AURKB does spe-
cifically play a key role in the regulation of XIST RNA bind-
ing to the inactive chromosome, providing the first knowledge 
of the specific players controlling this interaction. Results in-
dicate that AURKB activity is required for the normal release 
of human XIST RNA, which occurs in mitotic prophase, and 
further suggest that this role of AURKB is independent of   
its role in orchestrating chromosome segregation at anaphase 
(see Discussion).
H3ph is not sufficient for XIST  
RNA release
These findings now make it possible for the first time to manip-
ulate XIST RNA chromosomal binding as a new approach to 
investigate  chromatin-associated  factors,  either  upstream  or 
downstream of the change in XIST RNA’s binding. Because 
essentially nothing is known about this and there are many factors 
potentially involved, any information that narrows the possibili-
ties is valuable.
Mitotic histone phosphorylations on H1 and H3 are of 
particular interest because they both increase dramatically across 
chromosome arms at early prophase, during the same 5–10 min 
window when XIST RNA binding is altered. (Because mitosis 
takes <1 h, this window of prophase corresponds to just a few 
minutes.) However, the aforementioned results show that H1ph is 
not required for XIST RNA release because TAUT did not induce 
H1ph at interphase when XIST RNA released (Fig. 2, I and J), 
and H1 is not phosphorylated by AURKB. In contrast, H3ph may 
be required because H3ph (on both Ser10 and Ser28) is phos-
phorylated  by AURKB  (as  we  confirmed  by  inhibition  with 
HESP; Fig. S4 D), and we consistently saw XIST RNA released 
under conditions that also increased H3ph.
The first indication that H3ph does not itself lead to loss 
of  proper  XIST  RNA  binding  comes  from  comparing  the   
detailed timing of each of these in human versus mouse mitotic 
cells. Previous studies have shown that mouse cells retain the 
interphase-like  binding  affinity  of  XIST  RNA  longer  into   
mitosis (Fig. S2), with some cells still showing RNA associated 
with the chromosome into anaphase (Clemson et al., 1996; Lee 
and Jaenisch, 1997; Duthie et al., 1999; Smith et al., 2004), 
although we find that it is ultimately released before G1. This 
release of XIST RNA occurs significantly after the increased 
histone phosphorylation seen along the chromosome arms at 
prophase (Figs. S2 and S3), suggesting that high levels of H3ph 
may not be sufficient to affect XIST RNA binding. However, 
the clearest evidence that H3ph is not sufficient came from 
analysis of H3ph after RNAi to AURKB. Unlike HESP treat-
ment, which blocked H3ph and caused XIST RNA retention at 
metaphase (Fig. S4, C and D), RNAi to AURKB also caused 
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can still occur under conditions that retain mitotic XIST RNA; 
thus, H3ph is not sufficient to release XIST RNA.
Given the aforementioned findings, we examined whether 
there may be unanticipated differences between the phosphory-
lation of H3S10 versus H3S28 because both could potentially 
be detected by the polyclonal antibody used (raised against 
H3S10ph) and both increase in concert at the onset of mitosis 
(via AURKB; Goto et al., 1999). To examine H3S10 and H3S28 
specifically,  we  obtained  monoclonal  antibodies  that  detect 
H3S10ph  and  H3S28ph  specifically.  Surprisingly,  although 
phosphorylation of both H3S10 and H328 increases at mitosis 
on all other human chromosomes, H3S10ph was not detected 
with the monoclonal antibody on the inactive X chromosome 
(Fig. 6, C–F), which was positively identified by the presence 
of macroH2A (Fig. 6 F). However, the inactive chromosome 
does still label with an antibody raised against H3S28ph (Fig. 
6 C; unpublished data). Thus, if H3S10ph is not present on 
the mitotic Xi, it can play no role in the compromised XIST 
RNA binding seen at prophase, although we cannot rule out the 
chromosomes continued to stain brightly for H3ph, which is 
similar to controls (Fig. 6, A and B).
The presence of H3ph after AURKB RNAi (in mitotic cells 
confirmed by IF to lack AURKB; Fig. 6, D and E) was surprising 
in light of several studies (primarily in HeLa cells), which re-
ported that AURKB was required for mitotic H3ph (of either 
Ser10 or Ser28; Fischle et al., 2005; Hirota et al., 2005; Terada, 
2006). We tested RNAi to AURKB in HeLa cells and confirmed 
that it does indeed block H3ph (Fig. S4, G and H), and HP1 re-
mains bound (Fig. S4, E and F), as previously reported for HeLa 
(Dormann et al., 2006). Thus, we demonstrate a reproducible 
difference between cell types. It’s possible that some functions 
of AURKB can be rescued in the primary fibroblast line (and in 
G3 cells) but not in HeLa cells. For example, Aurora C kinase 
can rescue the mitotic H3ph function in some cell types (Sasai   
et al., 2004) and would also be inhibited by HESP (Agnese et al., 
2007) but not RNAi to AURKB. Because HeLa cells have lost 
the Xi, we did not examine XIST RNA in these cells; neverthe-
less, the results in normal fibroblasts indicate that increased H3ph 
Figure 6.  H3S10ph and H3S28ph are dis-
tinct on the Xi, suggesting that H3S10 may 
not be involved in XIST RNA retention after 
AURKB  inhibition.  (A  and  B)  A  polyclonal 
antibody raised against H3S10ph lights up 
control  and  AURKB  RNAi–treated  cells,  in-
cluding  the  inactive  chromosome  (arrow) 
covered by XIST RNA. (C) The inactive chro-
mosome  (arrows)  labels  with  an  antibody   
specific  to  H3S28ph  but  not  with  a  mono-
clonal antibody specific to H3S10ph. (D and E) 
H3S10ph (monoclonal) is seen in both control 
and AURKB inhibited cells, except for a single 
chromosome (arrows). Small insets show DAPI 
DNA. (F) MacroH2A staining confirms that it 
is the inactive chromosome (arrows) that lacks 
monoclonal H3S10ph. Bars, 10 µm.JCB • VOLUME 186 • NUMBER 4 • 2009   500
no single modification to chromatin may control XIST RNA 
binding (see Fig. 10).
Of the many chromatin hallmarks on Xi,  
only ubiquitin shows a relationship to  
the presence of XIST RNA along  
the chromosome
Given  that  multiple  chromatin  factors  may  be  involved  in 
XIST RNA localization, we further extended this strategy to 
begin examining other Xi chromatin hallmarks to determine 
possibility that the monoclonal epitope is somehow masked. 
Regardless,  because  H3ph  increases  in  mitotic  cells  treated 
for RNAi to AURKB, when XIST RNA is retained (Fig. 6 B), 
H3ph alone cannot be responsible for the normal release of 
XIST RNA. However, because we find that H3ph occurs be-
fore XIST RNA release, it remains possible, for example, that 
H3S28ph is one of multiple required events. Because XIST 
transcripts likely have multiple binding sites (Wutz et al., 2002) 
and appear to bridge chromatin with nonhistone components of 
nuclear substructure (see Introduction; Clemson et al., 1996), 
Figure 7.  HP1- is still released from mitotic chromosomes after Aurora B inhibition, suggesting that the retention of HP1- is not required to induce reten-
tion of XIST RNA at metaphase. (A–C) Control Tig-1 cells. Metaphase cells (A, top cell) show abundant Aurora B (red) signal and absent HP1- (green). 
HP1- in prophase cell appears slightly yellow because AURKB (red) is also localized to the chromosomes at this time. (D–F) AURKB RNAi–treated Tig-1. 
Although RNAi eliminated Aurora B in some metaphase cells () and not others (+), both cell populations lack HP1- staining at mitosis (green). DAPI DNA 
channels are separated in C and F to confirm metaphase cells. Bars, 5 µm.501 PHOSPHORYLATION BY AURKB AFFECTS XIST RNA BINDING • Hall et al.
Although 9 of the 10 heterochromatin modifications illus-
trated in Fig. 8 were separable from the XIST RNA–binding 
pattern, this approach identified ubiquitination of Xi as one in-
teresting exception. In human (Smith et al., 2004) and mouse 
(de Napoles et al., 2004; Fang et al., 2004), the inactive X is 
markedly ubiquitinated on histone H2A throughout interphase, 
and it is transiently lost at some point during mitosis (Smith 
et al., 2004). To determine whether there is a temporal separation 
or order to the loss of XIST RNA and ubiquitin in somatic cells, 
we examined the two simultaneously on individual mitotic chro-
mosomes. Using an antibody against protein-bound ubiquitin 
(FK2), XIST RNA and ubiquitin are visible together along the 
inactive chromosome in prophase (Fig. 9 A), but as cells enter 
metaphase, XIST RNA releases, and only ubiquitin remains in 
a subset (38%) of mitotic cells, indicating that it remains 
for a short time (Fig. 9, B and D). Although ubiquitinated chro-
mosomes lacking XIST RNA were found, the converse was not 
seen. Ubiquitin is gone by late metaphase, when the only protein-
bound ubiquitin usually visible is in the cytoplasmic proteo-
somes seen before the metaphase/anaphase transition (Fig. 9 C; 
Marston and Amon, 2004). This suggests that loss of ubiqui-
tination on the Xi closely follows XIST RNA release.
If loss of ubiquitination in mitosis is dependent on XIST 
RNA removal, it should be retained together with XIST RNA 
into  late  metaphase  when AURKB  is  inhibited.  In AURKB 
RNAi–treated cells, both XIST RNA and ubiquitin are seen 
together well into late metaphase, when the proteosomes are 
visible at the metaphase/anaphase transition (Fig. 9, E–H). In 
some rare cases (<1% of cells), XIST RNA and ubiquitin can 
even be seen together into anaphase (Fig. S5 C). These cells ap-
pear to have only reduced AURKB sufficiently to retain XIST 
RNA but not to prevent anaphase (Fig. S5, A and B). Thus, con-
ditions that induce retention of XIST RNA in AURKB-depleted 
cells simultaneously preserve ubiquitin on the inactive mitotic 
chromosome. Although there are many more chromosome-
associated proteins that remain to be examined by this new 
approach, these results illustrate that this strategy can be used to 
narrow the candidate factors involved and indicates that chro-
matin ubiquitination is the modification studied thus far that 
is most closely linked to a robust presence of XIST RNA in 
mitotic cells (Fig. 8).
which are clearly separable from compromised XIST RNA 
binding and identify any that may be closely linked to or   
impacted by XIST RNA retention. These need not be direct 
targets of AURKB but could be impacted indirectly (e.g., HP1 
chromatin binding is released at mitosis as a consequence of 
AURKB-induced  H3ph;  Fischle  et  al.,  2005;  Hirota  et  al., 
2005). Although loss of XIST RNA in somatic cells does not 
result in the rapid loss of heterochromatin marks (Csankovszki 
et al., 2001), some chromatin properties may show a more 
immediate relationship to alterations in XIST RNA binding. 
If so, one would expect to see a change in status during mitosis, 
when XIST RNA binding is compromised, and a reversal of 
this by RNAi to AURKB.
As shown (see Fig. 8), we find that most of the Xi hall-
marks remain unchanged on the Xi throughout the cell cycle 
and show no change in mitosis, which is consistent with prior 
literature (Chadwick and Willard, 2002; Plath et al., 2003; 
Smith  et  al.,  2004;  Karachentsev  et  al.,  2005;  Xiao  et  al., 
2007). Therefore, compared with the behavior of XIST RNA 
at mitosis, it can be surmised that histone modifications such 
as H3K27me, H3K9me, H4ac, H3K4me, and H4K20me are 
not closely linked to changes in XIST RNA binding affinity in 
somatic  cells.  HP1  is  a  heterochromatin-associated  protein 
that is released from all chromosomes at mitosis as a direct 
consequence of AURKB-mediated H3ph (Fischle et al., 2005; 
Hirota  et  al.,  2005).  HP1  has  an  RNA-  and  DNA-binding   
domain, and evidence suggests that its chromatin binding may 
be  dependent  on  an  unknown  RNA  (Maison  et  al.,  2002; 
Muchardt et al., 2002). Therefore, it was of particular interest 
to examine HP1 in cells inhibited for AURKB. Inhibition 
with HESP resulted in loss of mitotic H3ph and the abnormal 
interphase-like retention of both XIST RNA and HP1 (Fig. S4, 
A and B). However, in fibroblasts and G3 cells treated with 
AURKB RNAi, histone H3 was still phosphorylated (using 
the polyclonal antibody; Fig. 6 B), which caused HP1 to be 
released (Fig. 7), but XIST RNA was still retained on the 
chromosome. Therefore, results are consistent with the pub-
lished literature showing a link between H3ph and HP1 (Fischle 
et al., 2005; Hirota et al., 2005; Terada, 2006) but also indicate 
that loss of the HP1- isoform is not sufficient to cause XIST 
RNA release.
Figure 8.  Strategy to narrow the candidate 
factors  involved  in  XIST  RNA  binding.  The 
ability  to  manipulate  XIST  RNA  behavior  in 
vivo provides a strategy to determine which 
chromosome/chromatin-associated  proteins 
most  closely  mirror  the  binding  pattern  of 
XIST RNA. Of the 10 chromosome-associated   
proteins examined in this study, only 4 show 
the  requisite  fluctuations  in  mitosis  when   
XIST RNA is released (H3S10, H3S28ph, HP1, 
and  ubiquitin).  Of  these  four,  only  ubiquitin   
was  differentially  affected  in  AURKB  RNAi–
treated cells coincident with XIST RNA (aster-
isks indicate completely concordant patterns). 
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present across the chromosome arms. Third, results unexpect-
edly identify AURKB as a key player, independent of its role 
in the mechanics of mitosis, and expand our knowledge of the 
biological roles of AURKB, an extremely important, heavily 
studied enzyme which is commonly overexpressed in cancer. 
Although AURKB was known to phosphorylate mitotic chroma-
tin, it was not known to have any role in maintaining noncoding 
RNA on heterochromatin. Fourth, our findings regarding H3S10ph, 
H3S28ph, HP1, ubiquitination, and several other chromatin mod-
ifications substantially advance and narrow the potential candi-
dates for chromatin/nuclear factors that are closely linked to 
XIST RNA binding and identify one that appears to be closely 
impacted by the presence of XIST RNA.
Although AURKB’s most-studied role is at the mitotic 
centromere and spindle, our findings point to a new role in-
volved in RNA interaction with heterochromatin, implicating 
Discussion
Despite over a decade and a half of research, extremely little is 
known  as  to  how  XIST  RNA  faithfully  binds  and  localizes 
across its chromosome of origin. This study provides some in-
roads into the mystery of how a large noncoding RNA interacts 
with chromatin. First, it was a significant step to define condi-
tions by which XIST RNA’s interphase binding or mitotic re-
lease can be manipulated. This approach to manipulate XIST   
RNA in situ may provide a means to break the impasse in under-
standing how a large chromosomal RNA actually interacts   
with complex chromosomal and nuclear structure. Second, find-
ings in this study further support and extend earlier evidence 
(Clemson et al., 1996) that XIST RNA’s relationship to the 
chromosome does not strictly depend on hybridization to chro-
mosomal DNA but is regulated by interaction with a protein 
Figure 9.  After AURKB RNAi, increased retention of XIST RNA on metaphase chromosomes is paralleled by increased retention of ubiquitin. (A, C, and E) In 
G3 control cells, ubiquitin and XIST RNA are shown in prophase (A), early metaphase (C), and late metaphase (E). Normally, XIST RNA detaches early 
in prophase, and the ubiquitin mark (on histone H2A; Smith et al., 2004) is lost shortly thereafter. (G) The graph shows quantification in control cells.   
(B, D, F, and H) In AURKB RNAi–treated cells, both XIST RNA and ubiquitin stay on the chromosome throughout prophase (B) and metaphase (D) and   
into late metaphase (F), as quantified in the graph (H). Both XIST RNA and ubiquitin (Ub) are found together in 70% of metaphase cells after AURKB 
inhibition. Bar, 10 µm.503 PHOSPHORYLATION BY AURKB AFFECTS XIST RNA BINDING • Hall et al.
idea that AURKB’s effect on XIST RNA binding can be sepa-
rated from its role in the mechanics of mitosis. Instead, AURKB 
impacts, either directly or indirectly, the numerous XIST RNA 
anchor points along the chromosome arms. Although we can-
not rule out that this could occur via AURKB regulation of 
some other chromatin-modifying enzyme, the fact that AURKB 
localizes to chromosome arms when XIST RNA detaches and 
that AURKB is known to modify several chromatin proteins 
make it most likely that AURKB’s effects on XIST RNA binding 
are related to and possibly downstream of its know modifica-
tions to chromatin.
Activation of AURKB is very complex; not only is it 
repressed by PP1 at interphase, but activation also requires 
INCENP for full activity (Ruchaud et al., 2007; for review see 
Andrews et al., 2003), and both AURKB and INCENP can be 
sequestered in the cytoplasm during parts of the cell cycle   
(Rodriguez et al., 2006). This may in part explain why inhibi-
tors of PP1 did not consistently result in mislocalized XIST 
RNA in all cells, whereas inhibition of AURKB more reliably 
caused robust retention of XIST RNA at metaphase. However, 
this may also relate to the likely presence of multiple interphase 
anchor points, as further discussed in the next paragraph.
An  important  concept  for  understanding  the  effects  of 
various perturbations is presented in the model in Fig. 10. This 
model proposes that XIST RNA has multiple anchor points that 
bind it to chromatin. This is likely, given the large size (14 kb) 
of the transcript (Brown et al., 1992), evidence that multiple 
parts of the RNA contribute to its chromosomal localization 
(Wutz et al., 2002), and further evidence that XIST RNA bridges 
chromatin and nonchromatin components of interphase nuclear 
structure (Clemson et al., 1996). This redundancy of binding 
sites may assure the RNA’s very tightly restricted localization in 
cis and lack of promiscuous localization and silencing of neigh-
boring chromatin in trans. Importantly, the perturbation of any 
one protein-binding site would then be unlikely to release XIST 
RNA at interphase, although maintenance of a single binding 
site could still be sufficient to retain XIST RNA at metaphase, 
as illustrated in Fig. 10. This in turn fits with our observations in 
AURKB’s impact on chromosomal proteins. AURKB’s multi-
ple functions during mitosis are intimately linked to its chang-
ing cellular localization; thus, it is significant that AURKB is 
only present on the chromosome arms in mitosis during the 
same brief prophase window when XIST RNA binding changes 
(Crosio et al., 2002). AURKB is a key component of the chro-
mosomal passenger complex (CPC), a four-subunit complex 
which promotes chromosome alignment, cytokinesis, and mul-
tiple mitotic functions (for review see Vader et al., 2006). This 
four-subunit  complex  is  distinct  from  the  two-subunit  CPC 
complex (inner centromere protein [INCENP] and AURKB) 
that transiently localizes across the chromosome arms during 
prophase (when XIST RNA is released), where it is known to 
phosphorylate histone H3. By metaphase, the CPC localizes to 
centromeres, then microtubules, and finally the midbody. Its   
intracellular localization is correlated with its particular functions 
at each mitotic phase.
Several observations indicate that chromosome conden-
sation or other mechanical features of mitosis are not necessary 
to regulate XIST RNA binding. We show that XIST RNA can 
be released by specific manipulation at interphase and can still 
be retained on fully condensed metaphase chromosomes under 
certain conditions and further demonstrate that mitotic arrest 
alone, with other agents (NOC), had no effect on XIST RNA 
release (unlike AURKB inhibition). Because numerous XIST 
transcripts bind all along the chromosome, a change in this 
binding necessarily involves changes that occur throughout the 
length of the chromosome, which is consistent with AURKB’s 
early mitotic localization to the chromosome arms and its known 
effects on chromatin phosphorylation. In a small subset of cells 
in which AURKB had been reduced (but not eliminated) by 
RNAi, AURKB was sufficiently depleted across the chromo-
somes to cause retention of XIST RNA but was not low enough 
to fully prevent anaphase progression. Therefore, it is likely that 
more AURKB is required to coat the chromosome arms and 
modify proteins that impact XIST RNA than the smaller amount 
required to localize to just the centromeres and centriole for 
chromosome segregation. All of these observations support the 
Figure 10.  Model for multiple XIST RNA an-
chor points impacting its localization to chro-
matin. (Interphase) In normal interphase cells, 
XIST RNA is tightly bound to the chromosome 
because of protein interactions at multiple an-
chor points. The loss of a single anchor point 
may not be sufficient to release XIST RNA from 
the chromosome. (Mitosis) The normal loss of 
all anchor points at prophase in human cells   
releases  XIST  RNA  from  the  chromosome.   
Inducing the retention of a single anchor point 
is sufficient to significantly retain XIST RNA on 
the chromosome. This study shows that at least 
one of the anchor points involved in human 
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lost shortly after release of XIST RNA from the mitotic chromo-
some in somatic cells, suggesting that ubiquitination does not 
directly affect XIST RNA binding but may be affected by it. 
Additionally, upon depletion of AURKB and retention of XIST 
RNA, ubiquitin retention increases concomitantly, suggesting that 
normal loss of ubiquitin during mitosis depends on prior removal 
of XIST RNA. This is distinct from the reported requirement for 
Xist RNA to recruit the PRC1 complex responsible for the initial 
ubiquitination of Xi that occurs when chromosome silencing is 
first enacted during differentiation of mouse embryonic stem 
cells (Schoeftner et al., 2006). Interestingly, a recent study sug-
gests that H2A ubiquitination impairs the ability of AURKB to 
phosphorylate H3S10 (Joo et al., 2007). Thus, our results indicat-
ing that the Xi may lack H3S10ph could be related to this effect, 
and by the time XIST RNA and ubiquitin are both released dur-
ing mitosis, AURKB is no longer available on the chromosome 
arms to phosphorylate H3S10 on the Xi.
This study has developed the first system to systemati-
cally manipulate XIST RNA’s interaction with its chromosome 
and identified one major regulatory player (AURKB); however, 
this experimental approach could be expanded or refined in the 
future, as we anticipate other means will be found that release 
or retain XIST RNA. Although the use of pharmacological 
inhibitors has the obvious downside that drugs are not entirely 
specific (and may have different effects in different cell types), 
this may actually enhance the ability to release XIST RNA   
at interphase if multiple anchor points are indeed involved. 
For  example,  TAUT  or  OKA  may  impact  more  than  one   
anchor point, only one of which is the result of PP1 inhibition. 
Although not explored in depth, recent preliminary attempts to 
use RNAi to PP1 did not release XIST RNA, in contrast to the 
RNAi to Aurora B which consistently caused RNA retention at 
mitosis. However, the fact that only certain drugs released XIST 
RNA indicates that the result is not just a nonspecific effect. 
That one of the XIST RNA anchor points is abrogated by AURKB 
activation in interphase by these drugs was further supported 
by the fact that HESP could largely rescue the mislocalization 
phenotype despite the fact that simultaneous treatment with 
two such drugs increases the likelihood of nonspecific effects 
and toxicity.
A final important implication of these findings is that 
interaction of this noncoding RNA with heterochromatin is 
influenced by factors (such as AURKB) that can broadly affect 
chromatin, and thus, any change or perturbation that impacts 
the epigenetic and chromatin state of the cell could poten-
tially impact XIST RNA. This should be considered when 
interpreting any literature involving XIST RNA localization 
and could also relate to the finding that XIST RNA is some-
times mislocalized in cancer cells (Pageau et al., 2007b), and 
loss of the Xi is common in many tumors (Richardson et al., 
2006; for review see Pageau et al., 2007a). Thus, rather than a 
specific effect of a single factor such as BRCA1, mislocaliza-
tion of XIST RNA may occur through broad effects on chro-
matin, which may be impacted by other factors in addition to 
AURKB. Our results also raise the possibility that AURKB 
may impact the relationship of other regulatory noncoding 
RNAs with chromatin (for review see Bernstein and Allis, 
this study, in which it appeared more difficult to induce XIST 
RNA release in interphase than it was to cause atypical XIST 
RNA retention on human metaphase chromosomes.
Given that traditional biochemical approaches have not 
identified XIST RNA–associated proteins nor illuminated how 
transcripts bind the chromosome, this new approach to manip-
ulate XIST RNA binding in situ can provide inroads into the 
complexities of the RNA’s interaction with the chromosome. 
Although the problem is far from solved and will not likely 
prove tractable to a single interaction, our findings allow us to 
conceptualize and narrow the other potential players consider-
ably. Candidates for substrates involved in regulating human 
XIST RNA binding would need to be present across the chro-
mosome arms and change with XIST RNA both in normal 
prophase and with the manipulations to release or retain XIST 
RNA, as defined in this study (Fig. 8). Specific inhibition of 
AURKB by RNAi results in the preservation of at least one 
anchor point for XIST RNA at mitosis (Fig. 10), which nor-
mally would be directly or indirectly abrogated by AURKB. 
Although H3ph was initially the prime candidate, our surpris-
ing  finding  that  the  inactive  chromosome  appears  to  lack   
mitotic H3S10ph suggests that it may not be involved, although 
it will be important to evaluate this interesting distinction be-
tween X and autosome mitotic modifications more extensively 
(unpublished data). It is clear that increased H3S28ph alone is 
also not sufficient to release XIST RNA at mitosis, although it 
remains possible that H3S28ph is one of multiple binding sites 
and may still be required (Fig. 10). Additionally, the fact that 
H3S28 can be highly phosphorylated along the chromosome 
arms in mitosis without releasing XIST RNA rules out that 
increased negative charge across the chromosome induces 
mitotic release. Another strong candidate was HP1-, which is 
indirectly regulated by AURKB via H3ph to release from 
heterochromatin at mitosis, has an RNA-binding site (Maison   
et al., 2002; Muchardt et al., 2002), and is enriched on Xi in 
the cell types we study (Wreggett et al., 1994; Chadwick and 
Willard, 2003). However, our data show that XIST RNA can 
still remain bound when HP1- is released at mitosis, although 
this does not rule out that other HP1 subtypes ( and ) more 
closely mirror XIST RNA. Because XIST RNA may bridge 
chromatin with other nuclear structural elements (Fig. 10), 
nonhistone chromatin–associated factors (affected by AURKB) 
may also be involved. For example, the presence of two SMC 
(structural maintenance of chromosome) proteins, cohesin and 
condensin, are altered because of phosphorylation by AURKB 
early in mitosis when XIST RNA is released (Hauf et al., 2005; 
Lipp et al., 2007).
Although the inactive chromosome has numerous chroma-
tin hallmarks that help maintain its inactive state, most can be 
excluded as candidates for any immediate link to XIST RNA 
binding, primarily because they lack the requisite fluctuation dur-
ing mitotic prophase (Fig. 8). The inactive X stains brightly for 
ubiquitin and was shown to be markedly enriched for ubiquitina-
tion of histone H2A specifically (de Napoles et al., 2004; Fang   
et al., 2004). Unlike other Xi hallmarks, the ubiquitination mark 
was shown to be lost at some point during mitosis (Smith et al., 
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Cells were fixed in 4% paraformaldehyde for 10 min and then stored in 1× 
PBS or 70% EtOH. Loss of human XIST RNA at prophase was initially 
shown using four different fixation conditions (Clemson et al., 1996) and 
was further confirmed in this study by also testing three additional fixation 
procedures: (1) fixation before extraction in Triton X-100 for 3 min, (2) using 
proteinase K permeabilization instead of Triton X-100 (fix first, then rinse in 
70% EtOH followed by PBS, treat with 25 µg/ml proteinase K for 5 min, 
and then fix again), and (3) cytospinning with no permeabilization step 
before fixation.
FISH
Hybridization to RNA, DNA, and simultaneous DNA/RNA detection was 
performed as previously described (Johnson et al., 1991; Tam et al., 2002) 
or according to manufacturer’s directions (MP Biomedicals). DNA probes 
were nick translated with either biotin-11-dUTP or digoxigenin-16-dUTP 
(Roche). RNA-specific hybridization was performed under nondenaturing 
conditions under which the DNA was not accessible. In brief, RNA was hy-
bridized overnight at 37°C in 2× SSC, 1 U/µl RNasin, and 50% for-
mamide with 2.5 µg/ml of DNA probe. Cells were washed with 50% 
formamide/2× SSC at 37°C for 20 min, with 2× SSC at 37°C for 20 min, 
with 1× SSC at RT for 20 min, and with 4× SSC at RT for 5 min. Detection 
was performed using antidigoxigenin bound to 200 µg/ml rhodamine or 
2.5 mg/ml fluorescein-conjugated avidin in 1% BSA/4× SSC for 1 h at 
37°C. Postdetection washes were performed with 4× SSC, 4× SSC with 
0.1% Triton X-100, and 4× SSC for 10 min each at RT in the dark. For si-
multaneous RNA/DNA hybridizations, RNA hybridization was performed 
first (as above), and then the cells were fixed in 4% paraformaldehyde for 
10 min, DNA was denaturated, and DNA hybridization was performed. 
DNA was hybridized after denaturation. In brief, the cells were denatured 
in 70% formamide and 2× SSC at 80°C for 2 min before EtOH dehydra-
tion and air drying. Hybridization and detection were performed as de-
scribed above. Probes used for FISH were a 10-kb human XIST RNA gene 
construct (XIST RNA plasmid G1A), a probe against the human XIST RNA 
intron 1 and 2 (gift from H. Willard [Duke University Medical Center, Dur-
ham, NC] and C. Brown [University of British Columbia, Vancouver, British 
Columbia, Canada]), human Cot-1 DNA (Invitrogen), and chromosome 
4 paint (MP Biomedicals).
IF
IF and simultaneous protein/RNA detection were performed as previously 
described (Johnson et al., 1991; Tam et al., 2002). Most antibodies were 
used before RNA hybridization. In brief, slides were incubated in the 
appropriate dilution of primary antibody in 1% BSA, 1× PBS, and 1 U/µl 
RNasin for 1 h at 37°C (RNasin is added to protect RNA from possible 
RNase contamination of the primary antibody). Slides were washed, and 
immunodetection was performed using 1:500 dilution of appropriately 
conjugated (FITC or rhodamine) secondary (anti–goat, –mouse, or –rabbit) 
antibody in 1× PBS with 1% BSA. The antibody signal is fixed in 4% para-
formaldehyde for 10 min before hybridization (performed as detailed in 
the previous section), and all slides were counterstained with DAPI. Vecta-
shield (Vector Laboratories) was used as mounting media for all fluores-
cence imaging.
Antibodies  used  were  anti–HP1-  (Millipore),  anti-AURKB  (Bethyl 
Laboratories, Inc.), anti–phosphorylated histone H1 (clone 12D11; Milli-
pore),  polyclonal  anti-H3S10ph  (Millipore),  monoclonal  anti-H3S10ph 
(Millipore), anti-H3S28ph (Abcam), anti–acetylated H4 (Millipore), anti-
macroH2A  (Millipore),  and  anti–protein-bound  ubiquitin  (FK2;  Thermo 
Fisher Scientific). Previous studies used anti–ubiquitinated H2A (Millipore) 
in conjunction with FK2 to delineate the Xi (Fang et al., 2004; Smith et al., 
2004); however, this antibody is no longer available, and other commer-
cial ubiquitinated H2A antibodies were not validated for IF and did not 
work when tested.
Microscopy and image analysis
Digital imaging analysis was performed using a microscope (Axiovert 
200 or Axiophot; Carl Zeiss, Inc.) equipped with a 100× NA 1.4 Plan-
Apochromat objective and multi-bandpass dichroic and emission filter sets 
(model 83000; Chroma Technology Corp.) set up in a wheel to prevent 
optical shift. Images were captured with the AxioVision software (Carl 
Zeiss, Inc.) and a camera (Orca-ER; Hamamatsu Photonics) or a cooled 
charge-coupled device camera (200 series; Photometrics). Where rhoda-
mine was used for detection in red, a narrow bandpass fluorescein filter 
was inserted to correct for any bleed through of rhodamine fluorescence 
into the fluorescein channel. Most experiments were performed a minimum 
of three times, and typically 50–100 cells were scored in each experiment, 
2005). The role of epigenetics in cancer development has been 
increasingly recognized (Feinberg and Tycko, 2004; Esteller, 
2007; He et al., 2008), and these and other recent studies pro-
vide a framework for thinking about potential links between 
cancer and broad heterochromatic instability (for review see 
Pageau et al., 2007a). Because AURKB has been implicated 
in  several  cancers  in  which  overexpression  can  cause  cell 
transformation (Giet and Prigent, 1999) and is currently a tar-
get for chemotherapeutics (Girdler et al., 2006), it is impor-
tant to recognize the potential impact on chromosomal RNAs 
and heterochromatin.
Materials and methods
Cell manipulation and inhibition
Three different cell types were used to assess XIST RNA binding. WI-38 
and Tig-1 are both normal female fibroblasts, and the G3 cells are a sub-
clone of the F2-6 male HT1080 cell line containing an ectopic XIST RNA 
transgene that consistently silences and forms a well-defined Barr body 
(Hall et al., 2002). In G3 cells, the XIST RNA localization phenotype is 
very consistent throughout the population, and the abundant RNA is tightly 
localized to the chromosome 4 territory (Hall et al., 2002). This cell line 
provides a more robust and tighter localized XIST RNA signal than any 
normal female cell line we have studied. The Tig-1 and G3 cell lines were 
maintained in minimum essential media (Invitrogen) and 10% non–heat-
inactivated fetal calf serum with supplemental antibiotics. WI-38 human 
female fibroblast cells were grown in Basal Media Eagle (Invitrogen) and 
10% non–heat-inactivated fetal calf serum with supplemental antibiotics. 
For M-phase analysis of inhibitors, mitotic cells were dislodged from asyn-
chronously growing cultures and cytospun onto coverslips before fixation 
in 4% paraformaldehyde.
Drug treatments
Inhibitors used were HESP (obtained from Boehringer Ingelheim through 
B.D. Murphy, Université de Montréal, Montréal, Québec, Canada), OKA 
(Invitrogen and Sigma-Aldrich), STSP (Sigma-Aldrich), SB (Sigma-Aldrich), 
TSA (Sigma-Aldrich), CANTH (EMD), NOC (Tocris Bioscience), ZM (Tocris 
Bioscience), and TAUT (EMD). Drugs were dissolved in DMSO for stock   
solutions (10 mM HESP, 0.5 mM OKA, 100 µg/ml STSP, 0.22 g/ml SB,   
1 mg/ml TSA, 10 µM CANTH, 100 µM TAUT, and 2 mg/ml NOC) and 
used fresh or before 3 mo. Drugs were added directly to media over cells 
growing as a monolayer on coverslips typically for 4–6 h (and occasion-
ally  overnight)  before  being  assayed.  Working  concentration  ranges   
are as follows: 100 nM HESP, 0.5–1,000 nM OKA, 3–30 µM CANTH, 
0.5–9 µM TAUT, 39 mM SB, 0.03–66 µM TSA, 0.2–10 µM STSP, 330 nM 
NOC, and 0.05–1 µM ZM. The highest ranges of the inhibitors, OKA, 
STSP, TSA, CANTH, and TAUT, were usually lethal to the cell, as assessed 
by nuclear morphology, loss of cells from the slide, and high levels of cellu-
lar debris in culture. When used at high concentrations, all cells, including 
any floating, were cytospun onto coverslips for in situ assessment. The broad 
range kinase inhibitor STSP was used as a negative control for HESP and 
ZM. STSP did not cause XIST RNA to be retained on mitotic chromosomes. 
Metaphase arrest by NOC was also use as a negative control for HESP 
and ZM and did not cause XIST RNA retention.
RNAi
RNAi for AURKB was performed using the AIM1/AURKB SMARTpool from 
Thermo Fisher Scientific. DharmaFECT siRNA transfection reagent (Thermo 
Fisher Scientific) was used for primary Tig-1 cells, and Lipofectamine RNAiMAX 
(Invitrogen) was used on G3 cells according to the manufacturers’ proto-
cols. Negative controls for XIST RNA retention with AURKB RNAi were un-
treated cells as well as a 27-mer T-3 nonspecific control siRNA (sense, 
5-AACAAGGUUCUUAGUUAGACGUGACUG-3;  control  antisense, 
5-GUCACGUCUAACUAAGAACCUUGTT-3; Integrated DNA Technolo-
gies), which did not exhibit XIST RNA painting in metaphase.
Fixation
Our standard protocols for cell fixation have been described previously in 
detail (Johnson et al., 1991; Tam et al., 2002). In brief, for most experi-
ments, cells were grown on glass coverslips and extracted in cytoskeletal 
buffer, 5% Triton X-100, and vanadyl ribonucleoside complex for 1–3 min. JCB • VOLUME 186 • NUMBER 4 • 2009   506
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with a representative experiment shown. Key results were confirmed by at 
least two independent investigators. All findings were easily visible by eye 
through the microscope, and images were minimally enhanced for bright-
ness and contrast in Photoshop (Adobe) for publication. Digital morpho-
metrics was used to measure chromosome territories, where the signal 
intensity is digitally thresholded, and the computer defines the borders 
(MetaMorph program; MDS Analytical Technologies) and then measures 
the area within.
Online supplemental material
Fig. S1 summarizes the effects of other inhibitors of chromatin modifiers 
(acetylation and phosphorylation) on XIST RNA localization. Fig. S2 illus-
trates the link between H3S10ph and Xist RNA release in mouse mitotic 
cells. Fig. S3 compares the timing of H3S10ph in both mouse and human 
mitotic cells. Fig. S4 demonstrates that AURKB RNAi in HeLa cells does 
mimic what is observed in other cell lines treated with HESP. Fig. S5 shows 
that in rare anaphase cells partially inhibited for AURKB, XIST RNA and 
ubiquitin can be seen to mark the Xi. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200811143/DC1.
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